top of page

Enhanced Portfolio, Ease of Partnership

Created in 2019 by four European-based pharmaceutical companies, Aggrega Pharma is focused on enhancing
our partners portfolios by providing access to the most attractive generic drug product opportunities.

home

About

Aggrega Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members.  The shareholders are 4 European companies:

  • Bluepharma (Portugal)

  • Rafarm (Greece)

  • Substipharm (France) 

  • Welding (Germany)

sam-moqadam-2rrsfMN4hn8-unsplash%20(1)_e

Vision

Establish Aggrega Pharma as a premier partner to create a fully integrated pharmaceutical supply chain up to commercialization of drug product.

Science Lab

Strategy

Invest in Aggrega’s internal drug product portfolio through
utilizing Aggrega’s global development, financial strength,
and scale in sourcing and manufacturing footprint.

Partner using flexible commercial models to co-develop
and co-invest in generic drug products and select 505(b)2 opportunities.

Focus initially on US market and appropriately expand
concept ex-US.

Partnership

We are continually looking to expand and increase our finished dose portfolio through collaborative working – a core principle at Aggrega Pharma.

 

Our partnership combines flexible and innovative business models with collaborative process development to strengthen your products, while reducing your risk.

Business Handshake

Our partnership offering is supported by our network of development and commercial manufacturing facilities

at Bluepharma (Portugal) and Rafarm (Greece) as well as our network of finished dose CDMOs in Europe, North America
and Asia to meet your global product requirements.

About
vision
strategy
partnership
n2-01.png
1-01.png

PORTUGAL

GERMANY

3-01.png

FRANCE

4-01.png

GREECE

icones novos_Prancheta 1 cópia.png

Combined Revenue

>$500M/Year

icones novos_Prancheta 1 cópia 2.png

Combined Employees

>1200

icones novos_Prancheta 1 cópia 3.png

Countries

60+

icones novos_Prancheta 1 cópia 4.png

Global Product Launches

100+

1-01.png
3-01.png
4-01.png

Headquarters

Coimbra, Portugal

Hamburg, Germany

Paris, France

Athens, Greece

Founded

2001

1955

1995

1976

Extended and Immediate Release

Oral Solid finished dose development and commercial manufacturing facilities (FDA inspected). Clinical study management expertise through Blueclinical. 

Develop, register, supply

and commercialize drug

products globally with focus

on various dosage forms, incl. niche, complex & high potent.

API sourcing, regulatory affairs & distribution.

Develop, supply

and commercialize

drug products (ex-US) with

focus on niche, complex

dosage forms. 

Sterile Injectable and Ophthalmic finished dose development and commercial manufacturing facilities (FDA inspected).

shareholders

Shareholders

partners

Team

ProfSergio_3.jpg

Sérgio Paulo Simões

Board Member

MITSOPOULOS_PHOTO[1].jpg

Aris Mitsopoulos

Board Member

_LFA9533.jpg

Lars Hallmayer

Board Member

Substipharm-858.jpg

Leopold Berthier

Board Member

giulia.jpg

Giulia Falcone

Executive Director

Substipharm-30.jpg

Sylvie Fondanayche

Executive Director

KK.jpg

Simon Knölk

Executive Director

Tobias_profile 2023_3.JPG

Tobias Silva

Executive Director

science-in-hd-KxLKiiCl0gA-unsplash.jpg

Portfolio

NEWTABLE_Prancheta 1.png

* Early Development

products

News

Picture4.png
Aggrega and Xiromed annouce successful launch of Ephedrine Sulfate Injection USP in the U.S. Market
1667558185108.png
Aggrega will be attending CPhI Barcelona

24 - 26 October 2023

Fira Barcelona Gran Via, Spain

DCAT.png
Aggrega will be attending DCAT Week 2024

March 18-21, 2024

New York City

news
contacts

Contact

Get in Touch

Follow Us On:

  • LinkedIn

© 2021 Proudly created with Wix.com

6 Arrow RD, STE 200

Ramsey, New Jersey 07446, USA

bottom of page